Trial Profile
Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Malignant thymoma; Thymoma
- Focus Adverse reactions
- 07 Sep 2023 Planned End Date changed from 30 Jun 2023 to 31 Dec 2024.
- 07 Sep 2023 Planned primary completion date changed from 30 Jun 2023 to 31 Dec 2024.
- 11 Nov 2022 Planned number of patients changed from 30 to 37.